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ABSTRACT
Background The introduction of molecular karyotyping
technologies facilitated the identification of specific
genetic disorders associated with imbalances of certain
genomic regions. A detailed phenotypic delineation of
interstitial 16p13.3 duplications is hampered by the
scarcity of such patients.
Objectives To delineate the phenotypic spectrum
associated with interstitial 16p13.3 duplications, and
perform a genotype-phenotype analysis.
Results The present report describes the genotypic and
phenotypic delineation of nine submicroscopic interstitial
16p13.3 duplications. The critically duplicated region
encompasses a single gene, CREBBP, which is mutated
or deleted in RubinsteineTaybi syndrome. In 10 out of the
12 hitherto described probands, the duplication arose
de novo.
Conclusions Interstitial 16p13.3 duplications have
a recognizable phenotype, characterized by normal to
moderately retarded mental development, normal
growth, mild arthrogryposis, frequently small and
proximally implanted thumbs and characteristic facial
features. Occasionally, developmental defects of the
heart, genitalia, palate or the eyes are observed. The
frequent de novo occurrence of 16p13.3 duplications
demonstrates the reduced reproductive fitness
associated with this genotype. Inheritance of the
duplication from a clinically normal parent in two cases
indicates that the associated phenotype is incompletely
penetrant.
INTRODUCTION
Chromosomal imbalances are a cause of genetic
disorders and often cause a syndromic phenotype.
The identiﬁcation of such imbalances on a genome-
wide level was until recently only feasible by
investigating metaphase chromosomes under
amicroscope. The latest developments inmicroarray
technology, however, enable assessment of copy
number of thousands to millions of loci across the
human genome at a resolution far surpassing that of
conventional karyotyping. The introduction of these
technologies into the diagnostic work-up of patients
with congenital disorders represents a revolution in
this ﬁeld, the importance of which cannot be over-
stated. It led to a vast improvement in the aetio-
logical diagnosis of patients with previously
idiopathic congenital abnormalities, mental retarda-
tion (MR) and/or psychiatric problems.1 It moreover
permitted the identiﬁcation and delineation of novel
microdeletion and microduplication syndromes,
thus allowing a more detailed assessment of the
phenotypic consequences associated with speciﬁc
chromosomal imbalances and more accurate and
targeted care and counselling of patients and their
parents.2 The present study describes the identiﬁ-
cation and delineation of a novel microduplication
syndrome, microduplication 16p13.3, which is
complementary to microdeletions of 16p13.3 that
cause RubinsteineTaybi syndrome (RTS).3
PATIENTS, MATERIALS AND METHODS
Patients described in this study were referred for
idiopathic MR and/or congenital anomalies. They
were followed in the collaborating centres, and
clinical data and informed consent were obtained
from all patients or their legal representatives. A
genome-wide copy number proﬁle of the patient
DNA was obtained by subjecting it to microarray
analysis using the Affymetrix 500K GeneChip
platform (patient 2), the genome-wide 105K V7
OLIGO array (a custom designed array manufac-
tured by Agilent Technologies Inc (Santa Clara,
California, USA), containing oligonucleotides as
probes chosen genome-wide with an average
interval of 30 kb plus an enrichment of probes in
most known regions associated with syndromes,
pericentromeric and subtelomeric regions) (patients
1, 3, 6 and 8), the Agilent 244K platform (patients 7,
9 and 11) or the Agilent 44K platform (patient 12),
all according to manufacturers’ recommendations,
or using a tiling resolution bacterial artiﬁcial chro-
mosome (BAC) array of chromosome 16 (patient 4)
as described.4 The duplication in patient 9 was ﬁrst
detected by a microdeletion multiplex ligation
dependent probe ampliﬁcation (MLPA) kit (MRC
Holland, Salsa MLPA P245) (Amsterdam, the
Netherlands). All genome coordinates mentioned in
this study are according to human genome build 18
(NCBI 36.1). The inheritance of each of these
duplications was investigated by analysing parental
samples using microarrays (patient 2) or targeted
approaches such as ﬂuorescent in situ hybridisation
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(FISH) (patients 1, 3, 4, 6, and 8), MLPA (patients 9 and 11) or
quantitative polymerase chain reaction (PCR) (patients 7 and 12).
Positions of segmental duplications were downloaded from the
segmental duplication database website (http://humanparalogy.
gs.washington.edu/build36/). The duplications in patients 2, 5
and 10 were previously reported.5e7
RESULTS
Nine patients with an interstitial duplication of 16p13.3 are
described for the ﬁrst time in the present study. Of the three
previously reported patients (patients 2, 5 and 10),5e7 we have
addedmore accurate genotypic and phenotypic data for patient 2.
The results from micro-array analyses for patients 1e4, 6e9 and
11e12 are depicted in ﬁgure 1 together with the reported results
from investigations in patients 5 and 10. The molecular data are
summarised in table 1. The duplication occurred de novo in 10
cases and was inherited from a clinically normal parent in two
cases (patient 3 (maternal) and patient 8 (paternal)).
Comparing the extent of all duplicated regions enabled the
delineation of a critically duplicated region, which contains
a single gene: CREBBP (ﬁgure 1). We also reanalysed the molec-
ular karyotype of the patient reported to have an interstitial
16p13.3 duplication by de Ravel,8 using a higher resolution
platform (Agilent 244K). This revealed that the duplication
described in this patient was not interstitial but terminal,
extending from 0 kb to 8633e8648 kb, and is 2e10 times larger
than the interstitial duplications in patients 1e12. This patient
was, therefore, not included in the present analysis.
There was no family history of birth defects except for patient
2, whose father had one brother with a congenital heart defect
who died at 8 months of age and one sister with a history of
cardiac arrhythmias, and patient 3, where both parents had heart
murmurs at birth that resolved spontaneously after a few years.
Phenotypically, interstitial duplications of 16p13.3 are asso-
ciated with variable mental development (ranging from normal
to moderately delayed), and occasional behavioural problems
such as attention deﬁcit hyperactivity disorders, aggressive
behaviour, and autism spectrum disorders. Pregnancy was
uncomplicated in most; the mother of patient 3 had one
abnormal non-stress test and mild oligohydramnios was noted,
and patient 12 had intrauterine growth retardation. There was
no exposure to alcohol or other known teratogens except in
patient 3, where the mother reported occasional alcohol
consumption in the ﬁrst weeks of pregnancy. Birth was at term
in all patients. Growth was normal in all individuals except
patient 12 who had precocious puberty.
Many patients shared similar facial features. There was
midfacial hypoplasia in young children and a longer face in older
individuals. The nose was prominent and had a bulbous tip, and
the eyes were often upslanting with narrow palpebral ﬁssures,
sometimes with ptosis. The upper lip typically was thin, and the
ears low set and/or protruding (ﬁgure 2). We frequently observed
mild abnormalities of the hands (the thumbs were often proxi-
mally implanted and short, ﬁngers were long and tapering, the
ﬁfth ﬁnger was often short, there was also often camptodactyly
or mild cutaneous syndactyly) and of the feet (club feet, camp-
todactyly, or syndactyly) (ﬁgure 2). Less frequent were other
anomalies of the skeleton (congenital hip dislocation, vertebral
fusion), the eyes (blepharophimosis, epicanthus inversus, stra-
bismus, astigmatism, or ptosis), and the heart (atrial septal
defect, tetralogy of Fallot). Occasional ﬁndings include inguinal
hernia (twice), precocious puberty, cryptorchidism (twice),
submucosal cleft palate, and mild periventricular heterotopia on
magnetic resonance imaging (MRI) examination of the brain. An
overview of the phenotypic data of the individual patients is
given in table 1. The frequent occurrence of features such as club
feet, camptodactyly of the toes and ﬁngers, congenital hip
dislocation, and incomplete extension of the elbows is indicative
of mild arthrogryposis in these patients.
A total of about 25 700 patients have been analysed for
duplication of the CREBBP gene in our centres. In this patient
population, 11 duplications of CREBBP were found, suggesting
a frequency of this duplication of around 0.043% in these
patients. As about 2e3% of live births ﬁt the inclusion criteria for
our patient cohort (multiple congenital anomaly/mental retar-
dation (MCA/MR)) and about 80% of these are idiopathic before
molecular karyotyping,9 we estimate the frequency of this
duplication to be 1 in 97 000 to 146 000 live births.
Three different mechanisms have been proposed to generate
chromosome imbalances: non-allelic homologous recombination
(NAHR), non-homologous end joining, and fork stalling and
template switching (FoSTeS).10 When a region is recurrently
Figure 1 Upper panel: the extent of the duplications identified in the present study. Light grey bars indicate normal copy number, black bars indicate
duplicated regions, dark grey bars indicate the breakpoint containing regions. Patients are ordered according to the telomeric breakpoint of the
duplication. Lower panel: a view of the University of California Santa Cruz (UCSC) genome browser (NCBI build 36.1, March 2006), illustrating the genes
mapped to the implicated region (first track), the regions that are copy number variable in the normal population (Database of Genomic Variants, second
track), and the regions that have paralogues in the human genome (Segmental duplicatione Seg Dup; third track). The transparent grey box demarcates
the smallest region of overlap. All breakpoints appear unique and do not map specifically in low copy repeats.
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found to be deleted as well as duplicated, NAHR has been
suggested as a potential underlying mechanism. However, similar
to the breakpoints of deletions in this region, all breakpoints of
duplications appear unique, arguing against a mechanism of non-
allelic homologous recombination. To further exclude a local
homology based molecular mechanism, we assessed the presence
of segmental duplications (SD; length >10 kb, over 90%
homology) in the breakpoint containing regions. SDs encompass
7.7% of the region between 1800e6500 kb, but none of the
breakpoints falls clearly within an SD, and only two out of 22
breakpoint containing regions (9%) encompass an SD. We
therefore exclude NAHR as the mechanism generating these
imbalances. The lack of recurrent breakpoints for the copy
number variations in these cases indicates other mechanisms,
such as non-homologous end joining or FoSTeS, as possibly
causative. There were no complex imbalances identiﬁed, a hall-
mark of the recently proposed FoSTeS mechanism, although the
resolution of the analysis was probably insufﬁcient to assess this
critically in most cases. None of the parents reported exposure to
known mutagens.
DISCUSSION
The present report details genotype and phenotype of nine
patients with an interstitial 16p13.3 duplication. Three patients
that were previously reported were also included,5e7 with more
precise genotypic and phenotypic data for one of these (patient
2).6 Careful assessment of the phenotypic features of these
individuals enabled the description of a characteristic phenotype,
with normal to moderately retarded mental development, mild
arthrogryposis-like anomalies of the musculoskeletal system
(club feet, congenital hip dislocation, or camptodactyly of the
ﬁngers and toes), mild facial dysmorphism that changes with age
and occasional anomalies of the heart (atrial septal defect,
tetralogy of Fallot).
It is noteworthy that all patients were selected for study
because of MR and/or congenital anomalies. There might thus
bedas in most genetic disordersda bias towards the more severe
end of the spectrum in the described phenotype; normal or
mildly affected individuals do not present at the genetics clinic.
In two instances the duplication was indeed found to be
inherited from an apparently normal parent (patients 3 and 8)
who had both followed normal schooling, function normally in
society, and do not present the typical face. However, the
frequent de novo occurrence (in 10 of 12 patients) indicates that
this duplication is associated in most cases with a reduced
reproductive ﬁtness. In line with this is the ﬁnding that CREBBP
duplications were never identiﬁed in genome-wide copy number
proﬁling studies of more than 4000 individuals recruited from
normal control populations.11e13 In the patient populations we
studied, we identiﬁed an interstitial 16p13.3 duplication in 11 out
of 25 700 individuals, suggesting that it occurs in about 0.043% of
patients with MR or birth defects.
Three typical patients (9, 10 and 11) carry a very small duplica-
tion (maximal sizes 356, 480 and 639 kb), indicating that this is the
critical region associated with the described phenotype. This small
region encompasses only six genes. Of these genes, CREBBP is the
most attractive candidate gene. The smallest region of duplication
overlap (186e260 kb in size) in the 12 described individuals
contains only the CREBBP gene. The distally ﬂanking gene,
ADCY9, is unaffected in patient 2. The proximally ﬂanking gene,
TRAP1, is only partially duplicated in patient 12, rendering the
extra copy probably not functional. CREBBP encodes a histone
acetyl transferase and thus functions as a transcriptional co-acti-
vator by decondensing chromatin and activating geneTa
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transcription. Heterozygous loss-of-function mutations and dele-
tions of this gene have been shown to cause RTS,3 14 demon-
strating that human development is sensitive to CREBBP dosage.
None of the recurrent phenotypic ﬁndings in our patients
associate speciﬁcally with a region proximal or distal to CREBBP
except for ptosis, which was found only in three patients with
a more telomerically extending duplication (patients 2e4). In
contrast to duplications extending to the subtelomere,15 inter-
stitial duplications are not associated with microcephaly or
growth retardation. Other features reported for terminal
Figure 2 Phenotypic features of patients 1, 2, 4 and 6e12. Please note that patient 2 has had a surgical correction for ptosis.
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duplications of 16p seem to associate with duplication of
CREBBP. These include heart defects, MR and the arthrogryposis-
like features.15
Reciprocal duplications are now being clinically delineated for
many of the previously described microdeletion syndromes.
Examples include 7q11.23 duplications (reciprocal to
WilliamseBeuren syndrome deletions),16 15q11.2 duplications
(reciprocal to PradereWilli and Angelman syndrome deletions),17
17p11.2 duplications (known as PotockieLupski syndrome,
reciprocal to SmitheMagenis syndrome deletions),18 22q11.2
duplications (reciprocal to DiGeorge syndrome deletions),19 20
Xq28 duplications (MECP2 duplications, reciprocal to Rett
syndrome deletions)21 and 17p13.3 duplications (reciprocal to
MillereDicker syndrome deletions).22 Some recurrent themes
are emerging. In general, the phenotypic manifestations of
reciprocal duplications are milder and much more variable than
those of the deletions. Of interest, non-penetrance, which we
documented in two cases with duplication 16p13.3, has also been
reported for several of these duplications (eg, dup 22q11.2, dup
15q11.2, .).17 19
The defects observed in reciprocal deletion and duplication
syndromes often involve the same organs or functionsdfor
example, the heart in DiGeorge syndrome and duplication
22q11.2, speech in WilliamseBeuren syndrome and duplication
7q11.23, the teeth in SmitheMagenis and PotockieLupski
syndromes, or the nerves in CharcoteMarieeTooth 1A and
hereditary neuropathy with liability to pressure palsies.23 24
Similarly, defects of the hands, feet and heart are seen in both
deletion and duplication of 16p13.3.
In some instances, an intriguing reciprocal phenotype is seen
in the deletion versus duplication. For example, 7q11.2 deletions
have high verbal functioning, compared to particular deﬁciencies
in speech and language development observed in the duplication
7q11.2.16 The bulbous nasal tip observed in the present patients
may perhaps be a reciprocal phenotype to the long columella seen
in RTS, the short and proximally implanted thumbs may be
reciprocal to the broad thumbs typical for RTS, and the
arthrogryposis-like feature arguably compare to the joint hyper-
mobility.25
The present ﬁndings indicate that normal CREBBP dosage is
restricted not only by a lower threshold (as demonstrated in RTS)
but also by an upper threshold. The described duplications most
likely cause only a slight increase in CREBBP expression, with the
normal genomic dose being only 33% lower than the dose upon
duplication. This poses signiﬁcant challenges to the recently
proposed strategy to treat RTS patients with histone deacetylase
inhibitors26: the dosage dependency of CREBBP suggests that
such pharmaceutical interventions will prove beneﬁcial in a very
limited range of concentrations only. On the other hand,
administering a precise dosage of histone acetyl transferase
inhibitors such as curcumin27 presents a valuable line of inves-
tigation to develop a therapy for the novel genomic disorder
produced by CREBBP duplication. Curcumin is a cell permeable
inhibitor of multiple cellular targets including CREBBP and p300
(a paralogue mutated in an allelic form of RTS), which is
currently being tested in clinical trials for neoplastic and immu-
nological disorders.28 Although errors in development will not be
curable by such strategies, the observed problems in mental
function might beneﬁt from this therapeutic intervention.
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